Showing results (41-50 of 57) with videos related to
Sort By:
Pageof 6
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.Cancer|November 1, 2005
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancerRalph G Zinner, Frank V Fossella, Gregory W Gladish, et al.Lung Cancer (Amsterdam, Netherlands)|March 12, 2004
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing diseaseRalph G Zinner, Bonnie S Glisson, Frank V Fossella, et al.Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I ClinicDenis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2014
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancerRalph G Zinner, Coleman K Obasaju, David R Spigel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trialRalph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, et al.Pageof 6